BioNTech SE
Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases.
Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases.
BioNTech is an innovative immunotherapy company founded in 2008. The company is dedicated to developing breakthrough therapies for cancer and other serious diseases. With a slogan of "Innovating groundbreaking therapies for cancer and serious diseases," BioNTech utilizes advanced mRNA technology and a diverse range of drug classes to create innovative solutions. The company's diverse portfolio includes mRNA-based drugs designed to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates within the Biopharma, Biotechnology, and Pharmaceutical industries.
In the latest funding round, Coalition for Epidemic Preparedness Innovations made a $145.00M Post-IPO Equity investment in BioNTech on 29 May 2024. This significant investment reflects trust in the company's potential and innovative approach to developing therapies.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $145.00M | 1 |
|
29 May 2024 |
| Post-IPO Equity | $150.00M | - | 14 Apr 2022 | |
| Grant | €375.00M | 1 | German Federal Ministry of Education and Research | 15 Sep 2020 |
| Post-IPO Equity | $250.00M | 1 |
|
29 Jun 2020 |
| Post-IPO Debt | $100.00M | 1 | European Investment Bank | 11 Jun 2020 |
No recent news or press coverage available for BioNTech SE.
We care about your data, and we'd love to use cookies make your experience better.
